Alliance Pharma PLC Director's Dealing (3108P)
October 09 2019 - 5:14AM
UK Regulatory
TIDMAPH
RNS Number : 3108P
Alliance Pharma PLC
09 October 2019
ALLIANCE PHARMA PLC
("Alliance" or the "Group")
Director's Dealing
Alliance Pharma plc (AIM: APH), the international healthcare
group, announces that it has received notice that on 7 October
2019, Peter Butterfield, Chief Executive Officer of Alliance,
exercised unapproved share options over 3,137,546 ordinary shares
of 1p each in the Company ("Ordinary Shares") under the Company's
Share Option Plans. The average exercise price was 34.5 pence.
Following the exercise, on 7 October 2019, Mr Butterfield sold
2,791,546 Ordinary Shares at a price of 73.5 pence per share.
Following these transactions, Mr Butterfield's total beneficial
interest in the Group is 374,376 Ordinary Shares, representing
approximately 0.07 per cent. of the Group's issued share
capital.
The 3,137,546 Ordinary Shares will be admitted to trading
pursuant to an existing block listing, and will rank pari passu
with the existing Ordinary Shares in issue.
The notification below, made in accordance with the requirements
of the EU Market Abuse Regulation, provides further detail.
Notification and public disclosure of transactions by persons
discharging managerial responsibilities and persons closely
associated with them.
1 Details of the person discharging managerial responsibilities/person
closely associated
a) Name Peter Butterfield
-------------------------- -------------------------------------------------
2 Reason for the notification
-----------------------------------------------------------------------------
a) Position/status Chief Executive Officer
-------------------------- -------------------------------------------------
b) Initial notification Initial Notification
/Amendment
-------------------------- -------------------------------------------------
3 Details of the issuer, emission allowance market participant,
auction platform, auctioneer or auction monitor
-----------------------------------------------------------------------------
a) Name ALLIANCE PHARMA PLC
-------------------------- -------------------------------------------------
b) Legal Entity 213800RYIWZA4Q5WPZ13
Identifier
-------------------------- -------------------------------------------------
4 Details of the transaction(s): section to be repeated for
(i) each type of instrument; (ii) each type of transaction;
(iii) each date; and (iv) each place where transactions
have been conducted
-----------------------------------------------------------------------------
a) Description of Ordinary shares of 1 pence each
the financial
instrument, type
of instrument GB0031030819
Identification
code
-------------------------- -------------------------------------------------
b) Nature of the a) Exercise of options
transaction b) Sale of Ordinary Shares
-------------------------- -------------------------------------------------
c) Currency GBP
-------------------------- -------------------------------------------------
d) Price(s) and Price(s) Volume(s)
volume(s)
-------------------------- ------------------------------- ----------------
a) 34.5 pence a) 3,137,546
b) 73.5 pence b) 2,791,546
-------------------------- ------------------------------- ----------------
e) Aggregated information a) 3,137,546 Ordinary Shares, weighted average
- Aggregated exercise price of 34.5 pence per Ordinary
volume Share.
- Price b) 2,791,546 Ordinary Shares, sold at a price
- Aggregated of 73.5 pence per Ordinary Share, totalling
total GBP2,051,786.31.
-------------------------- -------------------------------------------------
f) Date of the transaction 7 October 2019
-------------------------- -------------------------------------------------
g) Place of the London Stock Exchange, AIM
transaction
-------------------------- -------------------------------------------------
For further information:
Alliance Pharma plc + 44 (0)1249 466966
Peter Butterfield, Chief Executive Officer
Andrew Franklin, Chief Financial Officer
www.alliancepharma.co.uk
Buchanan + 44 (0)20 7466 5000
Mark Court / Sophie Wills / Hannah Ratcliff
Numis Securities Limited + 44 (0)20 7260 1000
Nominated Adviser: Freddie Barnfield
Corporate Broking: James Black
Investec Bank plc + 44 (0) 20 7597 5970
Corporate Finance: Daniel Adams /
Ed Thomas
Corporate Broking: Patrick Robb /
Tejas Padalkar
This information is provided by RNS, the news service of the
London Stock Exchange. RNS is approved by the Financial Conduct
Authority to act as a Primary Information Provider in the United
Kingdom. Terms and conditions relating to the use and distribution
of this information may apply. For further information, please
contact rns@lseg.com or visit www.rns.com.
END
DSHMMMGGGLGGLZM
(END) Dow Jones Newswires
October 09, 2019 06:14 ET (10:14 GMT)
Alliance Pharma (LSE:APH)
Historical Stock Chart
From Apr 2024 to May 2024
Alliance Pharma (LSE:APH)
Historical Stock Chart
From May 2023 to May 2024